These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 589594)

  • 1. Epipodophyllotoxin VM-26 in the treatment of childhood neuroblastoma.
    Rivera G; Green A; Hayes A; Avery T; Pratt C
    Cancer Treat Rep; 1977 Oct; 61(7):1243-8. PubMed ID: 589594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study of VM-26 in acute leukemia, neuroblastoma, and other refractory childhood malignancies: a report from the Children's Cancer Study Group.
    Bleyer WA; Krivit W; Chard RL; Hammond D
    Cancer Treat Rep; 1979 Jun; 63(6):977-81. PubMed ID: 380803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. VM-26, a new anticancer drug with effectiveness in malignant lymphoma: an Eastern Cooperative Oncology Group Study (EST 1474).
    Chiuten DF; Bennett JM; Creech RH; Glick J; Falkson G; Brodovsky HS; Begg CB; Muggia FM; Carbone PP
    Cancer Treat Rep; 1979 Jan; 63(1):7-11. PubMed ID: 369693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Hypersensitivity to VM-26].
    Köster B; Ritter J; Bode U
    Klin Padiatr; 1984; 196(3):178-80. PubMed ID: 6540829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allergic reactions to teniposide in patients with neuroblastoma and lymphoid malignancies.
    Hayes FA; Abromowitch M; Green AA
    Cancer Treat Rep; 1985 Apr; 69(4):439-41. PubMed ID: 3857970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preliminary evaluation of VM-26: a new epipodophyllotoxin derivative, in the treatment of urogenital tumours.
    Pavone-Macaluso M; Caramia G; Rizzo FP; Messana V
    Eur Urol; 1975; 1(1):53-6. PubMed ID: 786645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination chemotherapy with VM 26 and CCNU in primary malignant brain tumors.
    Seiler RW; Vassella F; Markwalder H
    Surg Neurol; 1979 Mar; 11(3):237-42. PubMed ID: 473022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical pharmacodynamics of continuous infusion teniposide: systemic exposure as a determinant of response in a phase I trial.
    Rodman JH; Abromowitch M; Sinkule JA; Hayes FA; Rivera GK; Evans WE
    J Clin Oncol; 1987 Jul; 5(7):1007-14. PubMed ID: 3598607
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-dose teniposide for refractory malignancies: a phase I study.
    de Vries EG; Mulder NH; Postmus PE; Vriesendorp R; Willemse PH; Sleijfer DT
    Cancer Treat Rep; 1986 May; 70(5):595-8. PubMed ID: 3708608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination chemotherapy with VM 26 and CCNU in primary malignant brain tumors of children.
    Seiler RW
    Helv Paediatr Acta; 1980 Mar; 35(1):51-6. PubMed ID: 7410103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sequential cis-platinum and VM26 in neuroblastoma: laboratory and clinical (OPEC regimen) studies.
    Pritchard J; Whelan R; Hill BT
    Prog Clin Biol Res; 1985; 175():545-55. PubMed ID: 4039448
    [No Abstract]   [Full Text] [Related]  

  • 12. Use of VM-26 as a single agent in the treatment of renal carcinoma.
    Hire EA; Samson MK; Fraile RJ; Baker LH
    Cancer Clin Trials; 1979; 2(4):293-5. PubMed ID: 394865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effectiveness of cis-dichlorodiammine-platinum in the treatment of advanced neuroblastoma].
    Ohnuma N; Takahashi H; Maie M; Etoh T; Tanabe M; Kuriyama Y
    Gan To Kagaku Ryoho; 1987 Oct; 14(10):2876-80. PubMed ID: 3662544
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative trial of two teniposide-based combination chemotherapy regimens for the treatment of advanced malignant lymphomas.
    O'Connell MJ; Anderson J; Merrill JM; Bennett JM; Glick JH; Berard CW; Neiman RS; Brodovsky HS
    Cancer Treat Rep; 1982 Dec; 66(12):2021-5. PubMed ID: 6814757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Use of preparation VM 26 (epipodophyllotoxin) for treating lymphomas in children and adults].
    Kondrat'eva NA; Gershanovich ML; Kondrat'ev VB; Lebedev VN; Vialushkin VIa
    Vopr Onkol; 1981; 27(4):82-7. PubMed ID: 7015693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical evaluation of sequentially scheduled cisplatin and VM26 in neuroblastoma: response and toxicity.
    Hayes FA; Green AA; Casper J; Cornet J; Evans WE
    Cancer; 1981 Oct; 48(8):1715-8. PubMed ID: 7197189
    [TBL] [Abstract][Full Text] [Related]  

  • 17. VM-26 as a second drug in the treatment of brain gliomas.
    Kessinger A; Lemon HM; Foley JF
    Cancer Treat Rep; 1979 Mar; 63(3):511-2. PubMed ID: 427830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Results of a clinical study of an epipodophyllotoxin preparation (VM 26) in children with hemoblastoses].
    Kondrat'eva NA; Makhonova LA; Maiakova SA; Vialushkin BIa
    Probl Gematol Pereliv Krovi; 1981 Apr; 26(4):12-6. PubMed ID: 7015318
    [No Abstract]   [Full Text] [Related]  

  • 19. Phase II trial of VM-26 in patients with metastatic malignant melanoma.
    Bellet RE; Catalno RB; Mastrangelo MJ; Berd D; Koons LS
    Cancer Treat Rep; 1978 Mar; 62(3):445-7. PubMed ID: 348313
    [No Abstract]   [Full Text] [Related]  

  • 20. Disseminated neuroblastoma in children older than one year at diagnosis: comparable results with three consecutive high-dose protocols adopted by the Italian Co-Operative Group for Neuroblastoma.
    De Bernardi B; Nicolas B; Boni L; Indolfi P; Carli M; Cordero Di Montezemolo L; Donfrancesco A; Pession A; Provenzi M; di Cataldo A; Rizzo A; Tonini GP; Dallorso S; Conte M; Gambini C; Garaventa A; Bonetti F; Zanazzo A; D'Angelo P; Bruzzi P;
    J Clin Oncol; 2003 Apr; 21(8):1592-601. PubMed ID: 12697885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.